ricochet64 / Shutterstock.com - University of Southern Denmark
9 December 2020AmericasSarah Morgan
Danish university sues Creative Biolabs over ‘antibody pirating’
The University of Southern Denmark (SDU) has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
19 March 2020 Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Biotechnology
27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Editor's picks
Editor's picks
Americas
19 March 2020 Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Biotechnology
27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Americas
19 March 2020 Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Biotechnology
27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.